PTC THERAPEUTICS, INC. 8K

PTC Therapeutics will acquire Sangamo’s BLA-stage Fabry gene therapy ST-920 out of bankruptcy for up to $211 million, aiming for FDA accelerated approval in 2026 and commercialization in 2027, pending court and regulatory approvals.

On August 12, 2026, PTC Therapeutics, Inc. announced that it has been selected as the winning bidder in Sangamo Therapeutics’ bankruptcy auction to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, for $111 million upfront plus up to $100 million in contingent regulatory milestones, with the transaction subject to definitive documentation, bankruptcy court approval, antitrust review and other customary conditions and expected to close in late Q3 or early Q4 2026; PTC plans to complete a rolling BLA submission for accelerated FDA approval in Q4 2026, targeting a potential commercial launch in 2027 and leveraging its existing rare disease regulatory and commercial infrastructure without incremental development or commercial build.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

8K

Source Type

fda

Accession

0001104659-26-095424

Alert Tier

8